Search Results - "Verrill, M W"

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring by Jones, A L, Barlow, M, Barrett-Lee, P J, Canney, P A, Gilmour, I M, Robb, S D, Plummer, C J, Wardley, A M, Verrill, M W

“…More women are living with and surviving breast cancer, because of improvements in breast cancer care. Trastuzumab (Herceptin ® ▾) has significantly improved…”
Get full text

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk by Barrett-Lee, P.J., Dixon, J.M., Farrell, C., Jones, A., Leonard, R., Murray, N., Palmieri, C., Plummer, C.J., Stanley, A., Verrill, M.W.

“…Anthracyclines are considered to be among the most active agents for the treatment of breast cancer. However, their use is limited by cumulative, dose-related…”
Get full text

Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children? by Verrill, M W, Judson, I R, Harmer, C L, Fisher, C, Thomas, J M, Wiltshaw, E

“…To determine whether age at diagnosis influences the behavior of Ewing's sarcoma and primitive neuroectodermal tumor (PNET). We reviewed the clinical features,…”
Get more information

Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma by Coley, H.M, Verrill, M.W, Gregson, S.E, Odell, D.E, Fisher, C, Judson, I.R

“…Multidrug resistance (MDR) is a widespread problem in the treatment of neoplastic diseases and may limit the effectiveness of treatment of adult soft tissue…”
Get full text

Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma by Hess, V., Verrill, M. W., Bomphray, C. C., Vaughan, M. M., Allen, M., Gore, M. E.

“…Background: Doxorubicin is an active compound in epithelial ovarian cancer (EOC), but adding it to carboplatin–paclitaxel causes toxicity. Toxicity can be…”
Get full text

The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours by Verrill, M. W., Judson, I. R., Wiltshaw, E., Thomas, J. M., Harmer, C. L., Fisher, C.

“…Background Ewing's sarcoma and primitive neuroectodermal tumour (ES/PNET) are rare, limiting opportunities for therapy studies in adults. Chemotherapy regimens…”
Get full text

Quantification of phosphorus metabolites in human calf muscle and soft-tissue tumours from localized MR spectra acquired using surface coils by Doyle, V L, Payne, G S, Collins, D J, Verrill, M W, Leach, M O

“…Metabolite concentrations determined from MR spectra provide more specific information than peak area ratios. This paper presents a method of quantification…”
Get more information

Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study by de Boer, R.H., Saini, A., Johnston, S.R.D., O'Brien, M.E.R., Ellis, P.A., Verrill, M.W., Prendiville, J.A., Walsh, G., Ashley, S., Smith, I.E.

“…Despite the introduction of systemic chemotherapy, inflammatory breast cancer (IBC) remains a disease with a poor prognosis. We performed this phase II study…”
Get full text

Chemosensitivity testing of fresh and continuous tumor cell cultures using lactate dehydrogenase by Coley, H M, Lewandowicz, G, Sargent, J M, Verrill, M W

“…We have examined the use of the LDH (lactate dehydrogenase) assay for chemosensitivity testing in established and primary cultures of sarcoma, leukaemia and…”
Get more information

Fcγ-receptor IIa polymorphism and cardiotoxicity in patients with breast cancer treated with adjuvant trastuzumab by Cresti, N., Jamieson, D., Verrill, M. W., Pinkilgton, M., Boddy, A. V.

“…Abstract only…”
Get full text

Single nucleotide polymorphisms and expression/amplification of HER2 in patients with breast cancer by Boddy, A. V., Cresti, N., Jamieson, D., Pinkilgton, M., Verrill, M. W.

“…Abstract only…”
Get full text

Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma by Jamieson, David, Cresti, Nicola, Verrill, Mark W, Boddy, Alan V.

“…Trastuzumab is a therapeutic monoclonal antibody against the Her2 oncoprotein, which is over-expressed in approximately 30% of breast cancers, and is now used…”
Get full text

Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC) by Verrill, M. W., Lee, J., Cameron, D. A., Agrawal, R., Coleman, R. E., McAdam, K., Wardley, A., Bowman, A., Ferrigan, L., Yellowlees, A.

“…Abstract only LBA1005 Background: Phase II studies of weekly paclitaxel (P) confirm this to be a well tolerated regimen in ABC with potentially superior…”
Get full text

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules by BODDY, Alan V, PLUMMER, E. Ruth, CALVERT, A. Hilary, TODD, Radha, SLUDDEN, Julieann, GRIFFIN, Melanie, ROBSON, Lesley, CASSIDY, James, BISSETT, Donald, BERNAREGGI, Alberto, VERRILL, Mark W

“…Purpose: To determine the safety, maximum tolerated dose, pharmacokinetics, and toxicities associated with administration of paclitaxel poliglumex (PPX,…”
Get full text

Susceptibility of fibromatosis cells in short-term culture to ifosfamide: a possible experimental treatment in clinically aggressive cases by Verrill, M W, Coley, H M, Judson, I R, Fisher, C

“…Purpose. Deep fibromatoses are large, often rapidly growing but benign soft tissue tumours. Although surgery is the mainstay of treatment, in unremitting and…”
Get full text